Tag Archives: Lilly

These Stocks Are Moving the Most Today: Eli Lilly, Fortinet, AppLovin, Sunrun, Airbnb, Duolingo, and More  Barron’s Stocks making the biggest moves midday: Firefly Aerospace, Fortinet, Duolingo, Eli Lilly and more  CNBC Stocks to Watch Thursday: Eli Lilly, Firefly, DoorDash, TSMC  The Wall Street Journal Biggest stock movers Thursday: ABNB, DKNG, LLY, PTON, DUO, and more  Seeking Alpha Stock Movers: Paycom, Fortinet, Lilly  Bloomberg.com Source …

Eli Lilly delivered strong second-quarter results on Thursday, but shares are plummeting because of disappointing data for a key late-stage trial. It’s forcing us to ask ourselves difficult questions about this once-loved stock. Revenue in the three months ended June 30 jumped 38% year over year to $15.56 billion, beating Wall Street expectations of $14.71 billion, according to LSEG. Adjusted …

Key Takeaways Results from a late-stage trial of Eli Lilly’s experimental weight loss pill were disappointing, sending shares of the drugmaker tumbling. The study found average weight loss from the treatment was below that of rival Novo Nordisk’s Wegovy. The news offset Lilly’s much better-than-expected quarterly results and guidance boost. Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical …

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm  The Wall Street Journal Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial; shares drop  CNBC Eli Lilly’s key obesity pill falls short of rivals, but the company still beat on earnings  statnews.com Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says  CNN Daily oral …

Eli Lilly Stock Dives After Earnings Beat. Here’s Why.  Barron’s Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says  CNN Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity  Eli Lilly and Company Lilly’s GLP-1 pill cuts body weight by 12.4% in …

Pill Causes Major Weight Loss in Eli Lilly Trial’s Results  The New York TimesView Full Coverage on Google News Source link

Lilly reports second-quarter 2025 financial results and raises guidance  Eli Lilly and Company Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar  CNBC Eli Lilly beats earnings for second quarter on strong GLP-1 sales, but stock dives on GLP-1 pill trial results  Yahoo Finance Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday  Barron’s Eli Lilly raises full-year …

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 sales guidance to $60 billion …

Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity  Eli Lilly and Company Eli Lilly’s obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval  CNBC Lilly’s Obesity Pill Cut Body Weight by 11% in Key …

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving way …